Mikhail Blagosklonny: Championing for Greater Understanding of Oncology

One of the greatest challenges in the fight against cancer is the inadequacy of crucial information that is pertinent in developing more effective treatment and management options. However, over the years scientists such as Mikhail Blagosklonny have made great progress in demystifying the scourge that has become one of the leading causes of death globally in a few short years. The professor at Roswell Park Cancer Institute who specializes in oncology is also a research scientist with several scientific publications touching on oncology and aging to his name. With more studies indicating that the manifestation of aging has some commonalities with that of cancer, the First Pavlov State Medical University of St. Petersburg trained oncologist believes that understanding the signaling pathways for aging especially Target of Rapamycin (TOR) has the potential of finding the treatment for more than just aging. It has the potential of treating of cardiovascular diseases, cancer and Parkinson’s disease among others.

Drawing from his years of scholarly experience working as a research scientist, professor across several institutions including New York Medical College, Mikhail Blagosklonny believes that conceptualizing the TOR signaling pathway can create a model that build upon previous studies into its potential. His hypothesis postulates that the popular cancer drug has the anti-aging qualities and hence can be used to extend the human lifespan. This is because it eliminates the hyper-immunity of the body that is responsible for aging of cells. He also holds that TOR-centric model is hinged on inactivation of genes responsible for extending lifespan, increasing cell senescence and eliminating age-related diseases. With lifespan extended, Mikhail Blagosklonny believes that new causes of death will emerge over time.

Scholarly and professional Dedication to Understanding Oncology

Mikhail Blagosklonny has unrivalled grasp of oncology and its related conditions such as aging. He is a renowned scholar in the field with two degrees. He specialized in internal medicine for Doctor of Medicine studies. For his Doctor of Philosophy studies, he specialized in cardiology and experimental medicine. He is strongly convicted that, with time, scientists will find a cure for both cancer and aging. He believes that Rapamycin, which is currently being used for this purpose, holds a greater potential of tackling these conditions. This is most of his researches have focused on cell-related topics including anticancer therapeutic, mitosis, tumor suppressors and signal transduction. His professional career, which has also seen him work as a research scientist at Ordway Research Institute, has also seen him research on apoptosis, mechanisms of aging, cell cycle and ontogenesis. Mikhail Blagosklonny is a reputable authority on the topic of oncology. This is why has dedicated his scholarly and professional life to researching and disseminating information on cancer. Towards this end, he cofounded the open access online medical journal, Oncotarget, which is published weekly in English. He also serves as the coeditor-in-chief for the multiple peer-reviewed journal and several others including Cell Cycle and Aging. Additionally, he lends his vast experience in oncology for several other journals as a member of the editorial board. This includes Cell Death & Differentiation and Cancer Biology & Therapy.

Erick Lefkofsky Cancer Fighting Startup Partners with Healthcare Organization

When he started Tempus in 2015, Eric Lefkofsky had a goal of seeing that every cancer patient received personalized cancer care. Through the provision of genomic sequencing services and analysis of molecular and therapeutic data, Tempus empowers physicians to make real time and data-driven decisions. There was no better way the startup could achieve this than partnering with healthcare organizations in the country.

Partnership with Mayo Clinic

In this partnership, Tempus will work with Mayo’s Center for Individualized Medicine where the former will carry out sequencing and molecular analysis for 1000 Mayo patients. The patients are participants of the of immunotherapy studies relating to lung cancer, breast cancer, lymphoma, bladder cancer, and melanoma click here.

The sequencing will help guide future treatment options avoiding cases where patients receive treatment that may not work. Physicians, on the other hand, are hopeful that the partnership will increase survival rates of the patients.

Personalized Medicine Partnership with Northwestern Lurie Cancer Center

Lurie Cancer Center is designated as one of the country’s Comprehensive Cancer Center that is dedicated to fighting cancer through the provision of precision medicine. Recently, the Institute started a new initiative called OncoSET which has a goal of providing customized treatment and personalized care for all cancer patients. With the new partnership, Tempus will act as the partner providing genomic sequencing and analysis.

Benefits of the Partnerships

Tempus has partnered with other cancer centers including Ruth University Medical Center. These partnerships are a great way of collecting extensive data. From data gathered, physicians will be in a better position to realize mutation patterns. With this kind of information at hand, pathologist and oncologists will know which treatment will work for which patients, visit facebook.

Use of technological infrastructure that collects, analyzes, and stores data that matches clinical trials makes things easy for physicians. In this case, Tempus will be acting as an operating system for oncologists whereby they can use the data collected to decide the way forward.

Eric Lefkofsky Philanthropic Deeds

In addition to his dire need to support physicians in their quest for seeking a cure for cancer, Eric Lefkofsky is involved in other charitable works. He mainly focuses his assets on helping medical research, health care, education, arts and culture, and human rights.

Eric contributes to these sectors through Lefkofsky Family Foundation, a charitable trust he started with his wife in 2006. When the foundation’s focus is supporting other charitable organizations around the world, most of the funds are focused on Chicago, Eric’s hometown.